Continual drug discovery efforts for transthyretin amyloidosis were made, resulting recent approval of several TTR gene-silencing agents in 2022 and anti-TTR monoclonal antibodies as well as small molecule stabilisers currently in clinical trial [26]. Here, TTR is linked to Familial transthyretin-related amyloidosis.